Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Jill Maaske"'
Autor:
Juan P. Frias, Paul D. Hockings, Lars Johansson, Jill Maaske, Lisa J. Suchower, John P.H. Wilding, Nayyar Iqbal
Publikováno v:
Diabetes, Obesity and Metabolism. 24:61-71
AIM To report the results of a 104-week extension to a 52-week study in which dapagliflozin plus saxagliptin (DAPA+SAXA) improved glycaemic control, liver fat and metabolic variables compared with glimepiride (GLIM) in participants with type 2 diabet
Autor:
Juan P. Frias, Donald C. Simonson, Marcia A. Testa, Guillermo Gonzalez‐Galvez, Anne L. Peters, Jill Maaske, Nalina Dronamraju, Eva Johnsson, Ricardo Garcia-Sanchez
Publikováno v:
Diabetes, Obesity & Metabolism
Aims To evaluate the efficacy and safety of dapagliflozin (DAPA) + saxagliptin (SAXA) compared with glimepiride (GLIM) in patients with type 2 diabetes who were inadequately controlled [glycated haemoglobin (HbA1c) 7.5–10.5% (58–91 mmol/mol)] on
Autor:
Nalina Dronamraju, Paul D. Hockings, Lars Johansson, John P.H. Wilding, Jill Maaske, Eva Johnsson, Ricardo Garcia-Sanchez
Publikováno v:
Diabetes, Obesity & Metabolism
DIABETES OBESITY & METABOLISM
DIABETES OBESITY & METABOLISM
Aim To assess the effects of dapagliflozin plus saxagliptin plus metformin versus glimepiride plus metformin on liver fat (proton density fat fraction) and visceral and subcutaneous adipose tissue volumes over 52 weeks of treatment. Materials and met
Publikováno v:
Diabetes. 67
Add-on therapy with a single oral antihyperglycemic agent is often insufficient to provide glycemic control in patients with type 2 diabetes (T2D) uncontrolled on metformin (MET) monotherapy. This randomized, parallel-group, double-blind, 52-week tri
Autor:
Paul D. Hockings, John P.H. Wilding, Lars Johansson, Eva Johnsson, Jill Maaske, Ricardo Garcia-Sanchez
Publikováno v:
Diabetes. 67
Oral administration of a fixed-dose combination of the SGLT2 inhibitor dapagliflozin (DAPA) and the DPP-4 inhibitor saxagliptin (SAXA) is approved for improving glycemic control in adult patients with type 2 diabetes (T2D). A 52-week, multicenter, ra